WO2010148323A3 - Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus-related virus - Google Patents

Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus-related virus Download PDF

Info

Publication number
WO2010148323A3
WO2010148323A3 PCT/US2010/039208 US2010039208W WO2010148323A3 WO 2010148323 A3 WO2010148323 A3 WO 2010148323A3 US 2010039208 W US2010039208 W US 2010039208W WO 2010148323 A3 WO2010148323 A3 WO 2010148323A3
Authority
WO
WIPO (PCT)
Prior art keywords
xmrv
treatment
virus
related
diagnosis
Prior art date
Application number
PCT/US2010/039208
Other languages
French (fr)
Other versions
WO2010148323A2 (en
Inventor
Judy A. Mikovits
Vincent C. Lombardi
Sandra K. Ruscetti
Francis W. Ruscetti
Original Assignee
Whittemore Peterson Institute For Neuro-Immune Disease
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US26893309P priority Critical
Priority to US61/268,933 priority
Priority to US22500009P priority
Priority to US61/225,000 priority
Priority to US61/225,877 priority
Priority to US22587709P priority
Priority to US22861609P priority
Priority to US61/228,616 priority
Priority to US61/228,624 priority
Priority to US22862409P priority
Priority to US12/575,467 priority patent/US20100167268A1/en
Priority to US24948609P priority
Priority to US12/575,467 priority
Priority to US61/249,486 priority
Priority to US61/318,392 priority
Priority to US31839210P priority
Application filed by Whittemore Peterson Institute For Neuro-Immune Disease filed Critical Whittemore Peterson Institute For Neuro-Immune Disease
Publication of WO2010148323A2 publication Critical patent/WO2010148323A2/en
Publication of WO2010148323A3 publication Critical patent/WO2010148323A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes

Abstract

Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV immunopeptide, an XMRV antigen, or an XMRV nucleic acid in a sample from a subject. Therapeutic methods of treatment with anti-retroviral agents are also disclosed. Further disclosed are assays for testing compounds having activity against XMRV.
PCT/US2010/039208 2009-06-18 2010-06-18 Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus WO2010148323A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
US26893309P true 2009-06-18 2009-06-18
US61/268,933 2009-06-18
US22500009P true 2009-07-13 2009-07-13
US61/225,000 2009-07-13
US22587709P true 2009-07-15 2009-07-15
US61/225,877 2009-07-15
US22861609P true 2009-07-26 2009-07-26
US61/228,616 2009-07-26
US22862409P true 2009-07-27 2009-07-27
US61/228,624 2009-07-27
US24948609P true 2009-10-07 2009-10-07
US12/575,467 2009-10-07
US61/249,486 2009-10-07
US12/575,467 US20100167268A1 (en) 2009-07-15 2009-10-07 Seroconversion assays for detecting xenotropic murine leukemia virus-related virus
US31839210P true 2010-03-29 2010-03-29
US61/318,392 2010-03-29

Publications (2)

Publication Number Publication Date
WO2010148323A2 WO2010148323A2 (en) 2010-12-23
WO2010148323A3 true WO2010148323A3 (en) 2011-02-10

Family

ID=43357072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/039208 WO2010148323A2 (en) 2009-06-18 2010-06-18 Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus

Country Status (1)

Country Link
WO (1) WO2010148323A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105709224A (en) * 2012-10-02 2016-06-29 吉纳罗公司 Compounds For Treating The Remyelination Blockade In Diseases Associated With The Expression Of HERV-W Envelope Protein

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603863A1 (en) 2005-04-07 2006-10-19 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer
US8183349B2 (en) 2009-06-30 2012-05-22 Abbott Laboratories Markers of XMRV infection and uses thereof
WO2012004276A2 (en) 2010-07-06 2012-01-12 Fondazione Telethon Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088820A1 (en) * 1999-03-19 2006-04-27 Biomerieux Detecting superantigen activity in a biological sample
WO2006110589A2 (en) * 2005-04-07 2006-10-19 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer
US20090124635A1 (en) * 2005-01-20 2009-05-14 Pfizer Inc. Chemical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088820A1 (en) * 1999-03-19 2006-04-27 Biomerieux Detecting superantigen activity in a biological sample
US20090124635A1 (en) * 2005-01-20 2009-05-14 Pfizer Inc. Chemical compounds
WO2006110589A2 (en) * 2005-04-07 2006-10-19 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOMBARDI ET AL: 'Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome' SCIENCE vol. 326, 23 October 2009, pages 585 - 589 *
MCCORMICK ET AL: 'Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate' NEUROLOGY vol. 70, 2008, pages 278 - 283 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105709224A (en) * 2012-10-02 2016-06-29 吉纳罗公司 Compounds For Treating The Remyelination Blockade In Diseases Associated With The Expression Of HERV-W Envelope Protein

Also Published As

Publication number Publication date
WO2010148323A2 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
Dreyling et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma
Sirota et al. Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation
Rice et al. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis
Swenson et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc
Spudich et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden
Biron et al. Biomarkers for sepsis: what is and what might be?
Ragonese et al. Mortality in multiple sclerosis: a review
Keogh et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke
White et al. Co-existence of chronic fatigue syndrome with fibromyalgia syndrome in the general population: a controlled study
Dolan et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms
Abassi et al. Cryptococcal meningitis: diagnosis and management update
Khan et al. Kidney function and mortality among patients with left ventricular systolic dysfunction
Langford et al. Predictors of disease progression in HIV infection: a review
McDougal et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay
Raymond et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage
Agarwal Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease
Mondello et al. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders
World Health Organization The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance
Imani et al. Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships
Zhao et al. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials
Ninomiya et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Bayles et al. Epigenetic modification of the norepinephrine transporter gene in postural tachycardia syndrome
Guerchet et al. Cognitive impairment and dementia in elderly people living in rural Benin, west Africa
Pavlov et al. Systematic review with meta‐analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease
Kurian et al. Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10790278

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 10790278

Country of ref document: EP

Kind code of ref document: A2